Springer Medicine
@Springer_Med
Followers
3K
Following
68
Media
163
Statuses
1K
Trustworthy, tailored, cutting-edge content for medical professionals who want to deliver the best possible care. #EdsChoice selections by the content team.
Joined March 2023
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment. Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD. Register now 👉 https://t.co/FC5WA4UQo2
#HepTwitter
0
1
0
People with #epilepsy have double the cardiovascular mortality of the general population, largely driven by modifiable risk factors. What do you need to consider when treating patients with coexisting cardiac conditions? 👉 https://t.co/Af9UR9isnU
#NeuroTwitter #CardioTwitter
springermedicine.com
Cardiovascular disease (CVD) is highly prevalent worldwide, affecting approximately 523 million people globally as of 2019 [ 1 ]. Similarly, epilepsy
0
0
0
#MedNews - The risk for cardiovascular events and all-cause mortality is lower among patients with primary #aldosteronism who have unsuppressed versus suppressed renin after mineral corticoid receptor agonist use. Full story 👉 https://t.co/lve7xFXACr
#EndoTwitter
springermedicine.com
The risk for cardiovascular events is lower in patients with primary aldosteronism who have unsuppressed versus suppressed renin after
0
0
0
#MedNews - #AI-driven transcutaneous peripheral nerve stimulation device improves upper limb function in people with essential tremor compared with a sham device. Full story 👉 https://t.co/yOTktRUalo
#NeuroTwitter
springermedicine.com
AI-driven transcutaneous peripheral nerve stimulation device improves upper limb function in people with essential tremor compared with a sham
0
0
1
Despite well-documented benefits, exercise interventions are often underutilized in the #MultipleMyeloma population. This review provides evidence-based strategies for developing safe and effective exercise programs for these patients. 👉 https://t.co/Z1Re6Gb2Oq
#OncTwitter
springermedicine.com
Multiple myeloma (MM) is a type of hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow …
0
0
0
#MedCase - The first reported case of gallbladder metastasis arising from stage IVB primary ovarian leiomyosarcoma, underscoring the importance of physician awareness of unusual metastatic patterns. 👉 https://t.co/g8o1WUkxcE
#OncTwitter
springermedicine.com
Leiomyosarcomas are sarcomas originating from smooth muscle and are classified as mesenchymal tumors [ 1 , 2 ], which can develop in nearly all
0
0
1
#MedNews - The FXR agonist #cilofexor does not slow down fibrosis progression in patients with noncirrhotic primary sclerosing #cholangitis. Full story 👉 https://t.co/fxEQ424ESy
#GastroTwitter
springermedicine.com
The FXR agonist cilofexor does not slow down fibrosis progression in patients with noncirrhotic primary sclerosing cholangitis.
0
0
0
Coronary artery disease can be clinically silent in patients with type 2 #diabetes, remaining undetected until acute events occur. What approaches and techniques can be taken to aid diagnosis and tailor prevention in this population? 👉 https://t.co/ekqJjZtncr
#CardioTwitter
springermedicine.com
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes. This population faces an increased risk of
0
1
1
Could an ‘obesity first’ approach, which favors proactive obesity treatment, redefine the management of chronic diseases, such as hypertension, type 2 diabetes, #MASLD, CVD, musculoskeletal disorders, and potentially #IBD? 👉 https://t.co/W6VOUq4ZcS
#Obesity #MedTwitter
springermedicine.com
Could an ‘obesity first’ approach, which favors proactive obesity treatment, redefine the management of chronic diseases?
0
2
2
Recent trials have shown survival benefits of intensified regimens in EGFR-mutant #NSCLC, but they come at the cost of increased toxicity and treatment burden. So which patients should receive up-front intensification? Find out here 👉 https://t.co/tR44KRssSw
#OncTwitter
0
0
0
#MedCase - Less than 1/3 of patients with #SusacSyndrome present the classic triad – encephalopathy, vision loss, and hearing loss. This case series highlights heterogeneity of symptoms and the effectiveness of personalized immunosuppressive therapy. 👇
springermedicine.com
Susac syndrome (SuS) is an autoimmune endotheliopathy affecting microvessels in the central nervous system (CNS), retina, and cochlea and thus can …
0
0
0
Many people with type 2 #diabetes do not achieve or maintain tight glycemic control despite the availability of several classes of glucose-lowering agents. What are the prospects for future non-insulin pharmacological approaches? 👉 https://t.co/p85fww1ncG
#T2D #MedTwitter
springermedicine.com
Many people with type 2 diabetes do not achieve or maintain tight glycemic control despite the availability of several classes of glucose-lowering
0
0
0
#MedNews - The FcRn blocker #nipocalimab significantly improves clinical disease activity in people with moderate-to-severe #SjögrenDisease and could be a promising approach for these patients. Full story 👉 https://t.co/dpkoGXddHz
#MedTwitter
springermedicine.com
The FcRn blocker nipocalimab significantly improves clinical disease activity in people with moderate-to-severe Sjögren disease, shows the phase 2
0
0
0
From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer. Watch the full interview 👉 https://t.co/gZiJOxR1l1
#OncTwitter #MedNews
0
0
0
With #AASLD2025 coming to a close, continue your learning on #ALD with our upcoming free webinar. Find out more about the advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease. 👉 https://t.co/RGT0vck37V
#MedEd
0
0
0
#MedNews - Seven-year data from PARTNER 3 show #TAVR and surgery have similar long-term outcomes in low-risk patients with severe aortic stenosis. Full story 👉 https://t.co/UhkLgPW59N
#CardioTwitter #VHD
0
0
2
#MedCase - A man with #GravesDisease and orbitopathy presented with bilateral pretibial myxedema. Oral #tofacitinib was initiated after transient response to intralesional glucocorticoids‒edema and orbitopathy improved within 1 month. 👉 https://t.co/MiK7ciXrOD
#EndoTwitter
springermedicine.com
A man with Graves disease and orbitopathy presented with bilateral pretibial myxedema. Oral tofacitinib was initiated after transient response to
0
0
1
CAR T-cell therapy for CNS tumors in children and adults induces unique neurotoxicities. Learn about the underlying mechanisms, clinical implications, and management approaches. 👉 https://t.co/FV1VFnSvyP
#OncTwitter #NeuroTwitter
0
0
0
Explore the integration of #semaglutide with medical nutritional therapy for the comprehensive management of #obesity, with a focus on the Mediterranean diet and very-low-energy ketogenic therapy. 👉 https://t.co/X7HIKQKsgc
#MedTwitter
springermedicine.com
Explore the integration of semaglutide with medical nutritional therapy for the comprehensive management of obesity, with a focus on the
0
0
0
#MedNews - A proof-of-concept study suggests that treatment with the JAK inhibitor #tofacitinib could increase skeletal muscle mass in patients with rheumatoid #arthritis. Full story 👉 https://t.co/isQb8YJAtc
#RheumTwitter
0
0
0
Combination therapies involving novel drugs hold promise for improving chronic #HepB outcomes, particularly in achieving a functional cure. What are these novel drugs and how might they be combined to improve efficacy? 👉 https://t.co/T0QXJBAlGe
#IDMed #MedTwitter
0
0
0